fda warning letter glp-1 october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Warns 25 Firms Over

The patient did not take any other medications during the three months before starting BGM0504, during the period of receiving the four injections, or in the three weeks following the fourth injection, until the onset of his illness (Table 1)

The study revealed that use of semaglutide was associated with a 42% lower risk of worsening mental illness compared to periods when the same individuals were not taking GLP-1 receptor agonists

In the fall of 2021, Wellstar Paulding Hospital was designated a Level IV Trauma Center by the Georgia Department of Public Health

Therefore, I listed only cancer cells under Section 2.2.7, which were clearly addressed as cancer cells in a context of tumor-associated research

(2015b)